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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).SUMMARYDuchenne muscular dystrophy (DMD) is a severe muscle-degenerative disease caused by a mutation in the dystrophin gene. Genetic
correction of patient-derived induced pluripotent stem cells (iPSCs) by TALENs or CRISPR-Cas9 holds promise for DMD gene therapy;
however, the safety of such nuclease treatmentmust be determined. Using a unique k-mer database, we systematically identified a unique
target region that reduces off-target sites. To restore the dystrophin protein, we performed three correction methods (exon skipping,
frameshifting, and exon knockin) in DMD-patient-derived iPSCs, and found that exon knockin was the most effective approach. We
further investigated the genomic integrity by karyotyping, copy number variation array, and exome sequencing to identify clones
with a minimal mutation load. Finally, we differentiated the corrected iPSCs toward skeletal muscle cells and successfully detected the
expression of full-length dystrophin protein. These results provide an important framework for developing iPSC-based gene therapy
for genetic disorders using programmable nucleases.INTRODUCTION
Duchennemuscular dystrophy (DMD) is a severe muscular
degenerative disease caused by loss-of-function mutations
in the dystrophin gene located on the X chromosome.
The dystrophin gene consists of 79 exons, and disruption
of the protein reading frame by small deletions, exon dupli-
cations, or loss of exons leads to DMD (Pichavant et al.,
2011). The large size of the dystrophin gene hampers the
delivery of therapeutic cDNA for gene augmentation.
Therefore, the delivery of truncated microdystrophin or
microutrophin by an adeno-associated viral (AAV) vector
(Okada and Takeda, 2013), lentiviral vector (Pichavant
et al., 2011), or Sleeping Beauty transposon (Filareto et al.,
2013) has been investigated for DMD gene therapy.
However, restoration of the full-length dystrophin protein
remains challenging. An exon-skipping approach that
modulates mRNA splicing patterns using antisense oligo-
nucleotides (Aartsma-Rus et al., 2009) has shown prom-
ising results in preclinical studies, but the effects are only
transient. Genomic correction using programmable nucle-
ases is an ideal approach that can correct the mutated dys-
trophin gene.
The development of programmable nucleases has
provided a powerful tool for modifying target genome se-
quences. In particular, the transcription activator-like
effector nuclease (TALEN) (Hockemeyer et al., 2011) andStem Cethe clustered regularly interspaced short palindromic
repeat (CRISPR) and CRISPR associated 9 (Cas9) endonu-
clease systems (Cong et al., 2013; Mali et al., 2013) provide
greater flexibility than meganucleases or zinc-finger nucle-
ases (ZFNs) with regard to selecting the target regions of in-
terest (Li et al., 2014). Several studies have demonstrated
the effectiveness of TALENs (Hockemeyer et al., 2011;
Ding et al., 2013a) and CRISPR (Ding et al., 2013b; Mali
et al., 2013) in human induced pluripotent stem cells
(iPSCs) for reporter knockin, gene knockout, and gene
correction. In fact, corrections of disease mutation by nu-
cleases in iPSCs have been reported for several diseases,
including a1-antitrypsin deficiency (Choi et al., 2013), epi-
dermolysis bullosa (Osborn et al., 2013), b-thalassemia (Ma
et al., 2013), AIDS (Ye et al., 2014), and Niemann-Pick Type
C (Maetzel et al., 2014).
Before the TALEN and CRISPR systems can reach clinical
application, however, target specificity must be improved,
as high off-target mutagenesis rates in human cells have
been reported (Fu et al., 2013; Hsu et al., 2013; Lin et al.,
2014), although some reports have shown otherwise
(Smith et al., 2014; Suzuki et al., 2014; Veres et al., 2014).
Since target specificity depends on the design of the target
site, the properties of the DNA-binding domain, and the
epigenetic status of the targeting site, the risk of off-target
mutagenesis should be examined with respect to each tar-
geting nuclease in a therapeutic setting.ll Reports j Vol. 4 j 143–154 j January 13, 2015 j ª2015 The Authors 143
A B Figure 1. Visualization of the Unique
Sequences in the Human Genome
(A) Example of the mapped unique k-mer
sequences at the exon 45 region of the
dystrophin gene. The mapped k-mers are
indicated in the bottom panel and the
coverage of the k-mers in each base position
is indicated by the gray histogram. Within
this region, unique sequences of 14- to
16-mer were identified.
(B) Pseudocolor dot plot for the depth of
unique k-mers and the number of potential
off-target sites. CRISPR-sgRNA targeting se-
quences (23 bp with ‘‘NGG’’ PAM, n = 84,947)
were randomly selected from the human genome and the depth of the unique k-mers and number of potential off-target sites (with up to 3 bp
mismatches allowance) for each sgRNA sequence were calculated. Note that higher depth correlated with fewer potential off-target sites.
See also Table S1.
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Correction of DMD iPSCs by TALEN and CRISPRImmortalized myoblasts have been used for restoration
of the dystrophin protein mediated by meganucleases
(Rousseau et al., 2011; Popplewell et al., 2013), ZFNs (Rous-
seau et al., 2011), or TALENs (Ousterout et al., 2013). How-
ever, although primary myoblasts can be derived from
patients, their clonal expansion requires transformation
by oncogenes such as hTERT. In contrast, iPSCs (Takahashi
et al., 2007) can be isolated from patients directly and still
maintain pluripotency and an unlimited self-renewal ca-
pacity. Accordingly, when conjugated with made-to-order
genetic correction technologies, human iPSCs derived
from a patient with a genetic disorder (Park et al., 2008;
Hotta et al., 2009) might be applicable to autologous trans-
plantation as ex vivo gene therapy (Sebastiano et al., 2011;
Soldner et al., 2011; Zou et al., 2011a, 2011b).
In this study, as a proof-of-concept of such gene therapy
for DMD, we performed and demonstrated genetic correc-
tion of the dystrophin gene in patient-derived iPSCs by us-
ing three different methods: (1) disruption of the splicing
acceptor to skip exon 45, (2) introduction of small indels
to modulate the protein reading frame, and (3) knockin
of the missing exon 44 to restore the full protein coding re-
gion. We then performed comprehensive genome-wide
mutation analyses to assess the risk of off-target mutagen-
esis in 14 iPSC clones treated according to the TALEN or
CRISPR approach. Our results demonstrate that genetic
correction by these approaches in patient-derived iPSCs
considerably lowers the risk of off-target mutagenesis and
thus holds promise for DMD gene therapy.RESULTS
Targeting a Unique Region in the Human Genome
The risk of off-target mutagenesis by programmable nucle-
ases is associated with the specificity of the target sequence.
For example, in the 23 bp of the single-guide RNA (sgRNA)144 Stem Cell Reports j Vol. 4 j 143–154 j January 13, 2015 j ª2015 The Auttargeting region, up to 5 bp mismatches may be tolerated,
which may lead to off-target mutagenesis (Fu et al., 2013;
Hsu et al., 2013). To avoid this, the target sequence must
be uniquely defined in the genome. Moreover, the unique-
ness should be preservedwhen considering fragments of the
sequence (i.e., 15 bp in length). Therefore, to systematically
identify short unique sequences in the genome, we compu-
tationally generated all possible combinations of short
k-mer sequences (k% 16) and searched the human genome
to determine how many identical sequences are found for
each k-mer sequence. We then extracted the unique k-mer
sequences only when they matched a single location (i.e.,
with no match to other regions; see Table S1 available on-
line). We stacked the mapped k-mer sequences as a histo-
gram to visualize their uniqueness in the sequence depth
of coverage (Koehler et al., 2011; Figure 1A). We confirmed
that the higher the depth of the unique k-mer, the lower
was the number of off-target sites, with up to 3 bp mis-
matches allowed (Figure 1B). Therefore, the genome regions
with a higher depth of unique k-mers were considered good
candidates for targeting by programmable nucleases, and
regions with no peak were not considered. The benefit of
this method is that it allows one to visually identify the
targetable site quickly. Based on the histogramof the unique
k-mers, we identified the 50 region of exon 45 in the dystro-
phin gene as a target site for designing TALENs and CRISPR-
sgRNAs (Figures 2B and S2A).Generation of Integration-free DMD iPSCs
ADMDpatientwas diagnosedwith a deletionof dystrophin
exon 44 by amultiplex ligation-dependent probe amplifica-
tion method. We performed a primer walking method to
sequence the deleted region and identified that the deleted
size was 75,484 bp (chrX: 32,215,020-32,290,503 [hg19]),
including exon 44 (Figure S1A). We generated iPSC lines
from fibroblasts obtained from this DMD patient usinghors
AB
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Figure 2. TALEN and CRISPR-sgRNA Are
Equally Active for Targeting the Dystrophin
Gene in iPSCs
(A) The three strategies used to restore the
reading frame of the dystrophin protein.
(B) We designed the Platinum-TALEN pair and
CRISPR-sgRNA1 within the peak of the unique
k-mer sequences, as indicated by the gray his-
togram, and in front of the de novo premature
stop codon, as indicated by the red hexagon.
(C) The activities of Platinum-TALEN and
CRISPR-sgRNA1 were analyzed by a restriction
enzyme (XcmI) sensitivity assay. The XcmI
digestion site (CCANNNNNNNNNTGG) was
located in the spacer of the TALEN and next to
the PAM sequence of the CRISPR-sgRNA1. The
intensity percentage of the undigested band
(703 bp) was used to calculate the mutation
efficiency.
(D) The frequency of deletions (black bar) and
insertions (gray bar) was analyzed by deep
sequencing for the region flanking the target
site. The percentages of sequence reads
corresponding to deletions, insertions, and
mutated XcmI sites (white bar) are plotted.
No TF, nontransfected control.
See also Figure S2.
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Correction of DMD iPSCs by TALEN and CRISPRthe integration-free episomal vector method (Okita et al.,
2011).We chose iPSC lines thatmaintained a normal karyo-
type (Figure S1B) and expressed pluripotency markers,
including TRA-1-60, SSEA5, OCT3/4, and NANOG (Figures
S1C and S1D). Pluripotency was also confirmed by the
in vivo teratoma formation assay (Figure S1E).
Strategies for Dystrophin Correction
To restore the dystrophin protein reading frame in iPSCs
fromtheDMDpatientwho lacked exon44,wedevised three
approaches: the first was to disrupt the splicing acceptor of
exon45, as the connectionof exons 43 and46would restore
the reading frame; the second was to induce a frameshift by
introducing small indels (insertions or deletions); and the
third was to insert exon 44 in front of exon 45 (Figure 2A).
We tested 15 pairs (five left and three right) of TALENs
using the Golden-Gate assembly method (Golden-TALENs)
(Sakuma et al., 2013a) and one pair of Platinum-Gate-based
TALENs (Platinum-TALENs) (Sakuma et al., 2013b), which
had nonrepeat-variable diresidue variations on the TAL
domain to enhance the activity. We found that the E/a pair
of Golden-TALENs and Platinum-TALENs showed the high-
est recombination activity, as assessed by the single-strand-
annealing (SSA) assay, in human embryonic kidney 293T
(HEK293T) cells (Figures S2B and S2C).
We also constructed five CRISPR-sgRNAs adjacent to the
TALEN cleavage sites and tested the cleavage activities us-Stem Ceing the SSA assay (Figure S2C). There were no significant
differences in the cleavage activities among the constructed
CRISPR-sgRNAs. Therefore, we used sgRNA1 for later exper-
iments because it was located within exon 45 and closer to
the splicing acceptor than the other sequences. We then
compared the activity of Platinum-TALEN and CRISPR-
sgRNA1 by performing a restriction enzyme sensitivity
assay, and found that both had similar activity in DMD
iPSCs (Figure 2C).
Whenwe examined themutationpatterns by deep ampli-
con sequencing of the target region, we found that both
TALEN and CRISPR gave similar percentages of ‘‘mutated
XcmI sites,’’ which was consistent with the XcmI-digested
sensitivity assay (Figures 2C and 2D). Interestingly, CRISPR
induced a slightly higher indel rate compared with TALEN
(Figure 2C), which suggested that the restriction enzyme
sensitivity assay is sensitive to the relative position of the
nuclease-targeting site and to restriction enzyme sites that
differ by only a few basepairs. We also noted that TALEN
produced fewer insertions compared with CRISPR-Cas9
(Figure 2D).
Correction of the Reading Frame Mutation Solely by
Nuclease Treatment
Wenext utilized the programmable nucleases to restore the
reading frame via disruption of the splicing acceptor (exon
skipping) or induction of a (3n + 1) bp frameshift (wherell Reports j Vol. 4 j 143–154 j January 13, 2015 j ª2015 The Authors 145
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Figure 3. Correction of the Dystrophin Gene by Exon Skipping and Frameshifting Solely by Nuclease Treatment
(A) Summary of the exon-skipping (ES) and in-frame (IF) correction approaches using the indicated nucleases without the donor template.
The DMD-c1 iPSC clone was derived by a retroviral method and the DMD-iPSC #1 (CiRA00111) clone was derived by an integration-free
episomal vector method. Sanger sequence analyses were performed for all picked clones to identify subclones that had indels. The number
of ES and IF clones is indicated.
(B) The deletion patterns induced by TALENs and CRISPR-sgRNAs were analyzed by deep sequencing of the target site. The numbers around
the pie charts indicate the deletion sizes found in more than 5% of sequence reads, and the numbers with an asterisk indicate deletions
that could restore the reading frame of the dystrophin gene. The boxed numbers indicate the deletion patterns flanked with local
microhomologies.
(C) For each of the sequence reads obtained by deep sequencing, microhomology motifs on both sides of the deletion were retrieved and
the distribution of the microhomology sizes was plotted.
See also Figure S3 and Table S2.
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Correction of DMD iPSCs by TALEN and CRISPRn is a nonnegative integer) without a donor template
(frameshifting). Platinum-TALEN or CRISPR/Cas9-sgRNA1
was introduced into DMD iPSCs and the subclones were
screened by Sanger sequencing of the target genomic
DNA (Figures S3A and S3B). As summarized in Figure 3A,
a total of 229 iPSC clones were analyzed, and 40 clones
showed indels at the target site. Among the 40 clones
with indels, six were identified as exon-skipping (ES)
clones and 12 were identified as frameshift-induced in-
frame (IF) clones. We chose two clones (ESH19 and ESH29)
with an 18 bp deletion spanning the splicing acceptor
site of exon 45, and three clones (IFH13, IFH30, and IFD28)146 Stem Cell Reports j Vol. 4 j 143–154 j January 13, 2015 j ª2015 The Autwith a 1 bp insertion as IF clones with minimal alterations
to the amino acid sequence (Figure S3B). We confirmed the
pluripotency of the genetically corrected clones by exam-
ining their expression of OCT3/4, NANOG, TRA-1-60,
and SSEA5 (Figures S1D and S3C). Functional pluripo-
tency was also confirmed by a teratoma formation assay
(Figure S3D).
Deletion Patterns Induced by TALENs and CRISPRs
In our indel pattern analysis, we observed that several
clones harbored identical indel patterns mediated by flank-
ing microhomology motifs. To further assess the indelhors
A B
C
Figure 4. Correction of the Full-Length Dystrophin Protein by Exon 44 Knockin
(A) Schematic overview depicting the exon 44 knockin strategy. Top line: structure of the dystrophin gene with the exon 44 deletion. The
vertical blue arrow indicates the TALEN/CRISPR cut site and the red bar indicates the intron 45 probe used for Southern blot analysis. Note
that we introduced silent mutations at the nuclease-targeting site within exon 45 of the donor template.
(B) Summary of the exon 44 knockin experiments. The picked clones were first screened by genomic PCR for targeted knockin of the donor
template and then by Southern blotting with EcoRI digestion and the intron 45 probe to confirm no additional integration. Successfully
targeted clones were further treated with Cre to remove the drug selection cassette flanked by the loxP elements.
(C) Southern blot of the knockin clones (clone names: TKII15, TKII17, and TKIE27 for TALEN-mediated knockin clones; CKIC2, CKIC4, and CKIC6
for CRISPR-mediated knockin clones) showing successful targeting at the designated site. Subsequent Cre treatment excised the loxP-
flanked drug selection cassette. The probe in intron 45 was used to detect EcoRI-digested genomic DNA fragments.
See also Figures S3B and S3C.
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Correction of DMD iPSCs by TALEN and CRISPRpatterns, we isolated the genomic DNA 2–3 days after
nuclease transfection (to avoid the effects of cellular expan-
sion) and analyzed them by deep sequencing of amplicons.
We observed several variations of indel patterns, but some
sizes of deletions were enriched in both TALEN- and
CRISPR-treated samples (Figure 3B). Computational anal-
ysis of the nuclease target site (In silico Genome Editing
and Analysis Tools, https://apps.cira.kyoto-u.ac.jp/igeats/)
led us to observe that microhomology motifs existed on
both sides of the deletion site (Table S2), consistent with
a recent report (Bae et al., 2014a). In our case, we found
that the 3–5 bp microhomology-mediated deletions led
to more than 30% of the deletion events analyzed (Fig-
ure 3C). This observation suggests that a cleavage site
flanked by microhomology sequences can generate prefer-
ential deletion patterns, potentially via microhomology-
mediated repair.
Correction of the Full-Length Dystrophin Proteinwith
a Donor Template
The deletion of exon 44 is the third or fourth most com-
mon deletion in DMD patients (Aartsma-Rus et al., 2009;
Tuffery-Giraud et al., 2009); however, the breakpoints of
each deletion vary among patients. In order to restoreStem Cethe full amino acid sequence of the dystrophin protein
for DMD patients who lack exon 44, we attempted to
knock in the deleted exon 44 in front of exon 45. We
constructed a donor template vector to conjugate exon
45 with exon 44 to share the same splicing acceptor site
together with a hygromycin-selection cassette flanked by
two loxP sites (Figure 4A). We utilized Golden-TALEN (E/
a), Platinum-TALEN, and CRISPR-sgRNA1 for the knockin
experiments.
The targeting donor was coelectroporated with TALENs
or Cas9/sgRNA expression vectors. After hygromycin selec-
tion and limiting dilution, we isolated several clones and
screened for knockin clones by PCR analysis. Regardless of
which nuclease we used, up to 90% of the analyzed clones
(46/48 forGolden-TALEN (E/a), 43/48 for Platinum-TALEN,
and 9/12 for CRISPR-sgRNA1) showed targeting of the
donor template at the target locus. We further confirmed
single-copy knockin clones by Southern blot analysis and
found that approximately 44%–87% of the clones had
a single copy at the targeted site (Figure 4B). We chose
two clones (TKII15 and TKII17) mediated by Golden-TALEN
(E/a), one clone (TKIE27) mediated by Platinum-TALEN,
and three clones (CKIC2, CKIC4 and CKIC6) mediated by
CRISPR-sgRNA1 for the subsequent experiments.ll Reports j Vol. 4 j 143–154 j January 13, 2015 j ª2015 The Authors 147
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Correction of DMD iPSCs by TALEN and CRISPRTo remove the selection cassette from the knockin
clones, we transiently treated the obtained clones with
the Cre expression vector to excise the hygromycin-se-
lection cassette. Successful excision was confirmed by
genomic PCR and Southern blotting (Figure 4C). We also
sequenced the chimeric exon 44-45 in the knockin clones
by Sanger sequencing, and detected no extra mutations
except for the five silent mutations (underscored in Fig-
ure S3B) that were designed to prevent the sequence from
being recut by our programmable nucleases. In addition,
we checked the expression of the pluripotency markers
OCT3/4, NANOG, TRA-1-60, and SSEA5 in the knockin
clones (Figures S1D and S3C).
Analyses of Off-Target Mutagenesis Induced by
TALENs or CRISPRs
The risk of undesired off-target mutagenesis is one of the
most important concerns for the application of genome-
editing technologies, and especially for gene therapy. We
designed our experiments so that all genetically corrected
clones originated from a single DMD-iPSC clone, which
allowed us to distinguish preexisting genetic variations or
culture artifacts in iPSCs (Laurent et al., 2011; Sugiura
et al., 2014) from nuclease-mediated mutagenesis. The
off-target effects were classified into two categories:
target-sequence-dependent and -independent mutations.
To assess the former, we searched for potential off-target
sites with several mismatches in the human genome using
the Bowtie program. For the Platinum-TALEN and Golden-
TALEN E/a pair target sequences, we found thousands of
potential off-target sites containing up to threemismatches
for one side of TALEN. However, no pairs were located
within 100 bp to form the FokI dimer. For the CRISPR-
sgRNA1, we found five predicted off-target sites containing
up to three mismatches (Figure S4A).
To investigate whether these potential off-target sites
were actually mutated, we amplified the predicted off-
target regions and analyzed them using the T7 endonu-
clease I (T7EI) assay. In contrast to the on-target cleavage,
four predicted off-target sites showed no detectable muta-
genesis, whereas one locus had a homozygous insertion
of the AluYb9 element with a poly A tail (39-mer) (Fig-
ure S4B). The poly A stretch generated a heteroduplex
when the PCR products were reannealed during the T7EI
assay, resulting in digestion by T7EI even in the nontrans-
fected control. We confirmed that the insertion of AluYb9
occurred in the original DMD fibroblasts and DMD iPSCs,
but not in Caucasian-derived control iPSCs (Takahashi
et al., 2007; Figure S4C).
To investigate the presence of minor mutations that
were not detectable by the T7EI assay, we performed
deep sequencing of the amplicons at the off-target
sites. No significant indel reads were observed above148 Stem Cell Reports j Vol. 4 j 143–154 j January 13, 2015 j ª2015 The Autthe background level of the nontransfected control
(Figure S4D).
Next, we examined whether nuclease treatment affected
the chromosomal structure at the single-cell level. We first
checked the karyotype of the genetically modified clones
by performing a chromosome count with conventional
Giemsa staining and high-resolution G-banding. Several
suspected clones identified by G-banding were further
analyzed by multicolor fluorescence in situ hybridization
or multicolor banding. The majority of the modified cells
(144/153, 94.1%) maintained a normal karyotype (Figures
5A and S5), but a few (9/153, 5.9%) showed a suspected
or abnormal karyotype in three clones (out of seven modi-
fied clones analyzed; Figures S5D and S5E). Interestingly,
it was previously reported that an amplification of
chr20q11.21 was associated with a growth advantage for
human embryonic stem cells (Amps et al., 2011). With
the TKII17 clone, we observed an inverted insertion at
chr20q11.2 (ins(20)p11.2q13.3q12) in two of the 30 meta-
phases we analyzed. This insertionmayhave been acquired
during the subcloning process.
It was previously reported that TALENs or CRISPR-Cas9
may induce up to 1 Mbp of deletions if two separated sites
are targeted simultaneously (Canver et al., 2014). To eluci-
date whether the off-target cleavage of TALENs or CRISPR-
Cas9 induced such large deletions or duplications, we
investigated DNA copy number variations (CNVs) in the
corrected clones by TALEN or CRISPR treatment with a
high-density SNP array. We detected several CNVs com-
pared with the reference data (human population mean),
including the 75 kbp deletion of dystrophin exon 44, vali-
dating our analysis (Figure S6).
We focused on the de novo CNVs that were not present
in the original DMD iPSCs, and found no major dif-
ferences in the number of CNVs among the three cor-
rected groups (Figure S6B). We employed three control
clones that were subjected to similar electroporation and
limiting dilution processes as the dystrophin-corrected
clones, but were unmodified at the target site. To de-
termine whether there was any correlation between the
potential off-target sites and the observed CNVs, we
measured the distance between the edges of the CNVs
and the potential nuclease cleavage sites. The distribu-
tions for each nuclease were comparable to the corre-
sponding numbers of randomly selected genomic loci
(Figure 5B).
Furthermore, we sequenced the whole protein-coding
regions of the original DMD-iPSC clone and their sub-
clones by exome sequencing (Table S3). To assess the sin-
gle nucleotide mutations associated with the treatment of
programmable nucleases, we used the parental DMD iPSC
as a reference and extracted the de novo mutations
observed only in the offspring clones. From this analysis,hors
AC
Karyotype analyses for DMD-iPSC and the corrected clones
Samples Cell type Chromosome number                 G-banding
44 45 46 47 48 Normal Abnormal Examined
DMD-Fibroblast Original 3 46 1 20 20
DMD-iPSC Original iPSC 50 20 20
IFH13
TALEN
in-frame
50 18 5 23
IFH30 50 18 2 20
IFD28 50 20 20
TKII15 TALEN
 knockin
50 20 20
TKII17 50 28 2 30
CKIC2 CRISPR
 knockin
1 2 46 1 20 20
CKIC4 2 48 20 20
Subtotal 1 4 344 0 1 144 9 153
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Figure 5. Multiple Whole-Genome Analyses Revealed No Severe
Off-Target Mutagenesis
(A) Summary of the karyotyping analyses of the corrected clones.
Conventional Giemsa staining was used for chromosome counting
(50 metaphases were counted), and high-resolution G-banding was
applied to detect chromosomal rearrangements (at least 20 meta-
phases were analyzed).
(B) SNP array analysis identifiedde novoCNVs in the corrected clones.
To determine associations between detected CNVs and potential off-
target sites, the distances between the edges of the detected CNVs
and potential nuclease target sites are plotted for each nuclease (red
cross for sgRNA1, green diamond for Golden-TALEN, and blue3mark
for Platinum-TALEN). Since the likelihoodof thedistancedistribution
depends on how many genomic sites are selected, we also selected
random genomic positions and calculated the distance for each CNV
(gray circles). A zero value in the y axis indicates the edge of the CNVs
and a negative value indicates the inside of the CNVs. If any given
nuclease off-target site is associated with the detected CNVs, the
target site should approximate zero distance.
(C) The number of single nucleotide variants (SNVs) and small in-
dels detected by exome sequencing. Only de novo SNVs and indels
that did not exist in the original DMD fibroblasts or DMD iPSCs are
plotted. Unmodified control clones underwent the same electro-
poration and subcloning process as the other corrected clones and
were sequenced at similar passage numbers.
See also Figures S4–S6 and Tables S3–S5.
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Correction of DMD iPSCs by TALEN and CRISPRwe identified a few dozen point mutations (both synony-
mous and nonsynonymous) and several indels from the
exome sequencing data (Figure 5C; Tables S4 and S5).
Importantly, we successfully detected the 1 bp insertion
and 18 bp deletion at the dystrophin exon 45 in the IF
and ES clones, respectively (Table S5, labeled in blue).
We observed slightly higher indel events (p < 0.05, one-
way ANOVA) in the CRISPR knockin clones (average
3.0) compared with the unmodified controls (average
0.33). However, most of the detected indels were in the
triple-repeat or GC-rich regions and were not associated
with potential off-target sites, which is consistent with
recent reports (Smith et al., 2014; Veres et al., 2014). In
addition, there were no significant differences in the
number of SNVs among the three correction approaches
and the control group (p > 0.05, one-way ANOVA), which
is also in agreement with recent publications (Smith et al.,
2014; Veres et al., 2014). Taken together, these results
show that no severe off-target mutagenesis was associated
with potential nuclease-targeting sites in the dystrophin-
corrected iPSC clones.
The Dystrophin Protein Was Restored in
Differentiated Skeletal Muscle Cells
To confirm that genetic correction by TALEN and CRISPR
resulted in restoration of the dystrophin gene products,
we differentiated the original and corrected iPSC clones
into skeletal muscle cells using our recently published
method (Tanaka et al., 2013). Differentiated skeletalmuscle
cells were collected on day 9 of differentiation to isolate
mRNA. Amplification using PCR primers spanning exons
43 and 46 revealed that the exon 44 knockin clone
(CKIC2) had restored the full-length dystrophin mRNA to
the same length as that of a healthy individual control
(‘‘Healthy’’; Figure 6A). Sanger sequence analysis of the
cDNA also showed the corresponding correction, where
the 1 bp insertion of ‘‘A’’ in the IF clone (IFH30), the 18 bp
deletion that induced the skipping of exon 45 (ESH29),
and the knockin clone (TKII15 and CKIC2) all led to success-
ful expression of the inserted exon 44 together with exon
45 (Figure 6B).
Finally, to detect the restored dystrophin protein, we per-
formed immunofluorescence staining with an anti-dystro-
phin antibody (Dys1), which recognizes the rod domain
(amino acids 1,181–1,388) of the dystrophin protein (Fig-
ure 6C). The restored dystrophin protein was localized
at the submembrane region, as expected, in all corrected
clones examined. Furthermore, we performed a western
blot analysis with an anti-dystrophin antibody, which rec-
ognizes amino acids 3,661–3,677, and detected bands at
the following predicted sizes: 420 kDa for the reading-
frame corrected clone, 414 kDa for the ES clone, and
427 kDa for the knockin clone (Figure 6D). As expected,ll Reports j Vol. 4 j 143–154 j January 13, 2015 j ª2015 The Authors 149
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Figure 6. Restoration of the Dystrophin Protein in Differentiated Myogenic Cells
(A) RT-PCR analysis for dystrophin cDNA from iPSCs and cells differentiated from the corrected clones toward skeletal muscle lineage. The
original DMD patient and an IF clone (IFH30) with 1 bp insertion corresponded to the 452 and 453 bp PCR bands, respectively. The healthy
control and knockin clones (TALEN-mediated TKII15 and CRISPR-mediated CKIC2) corresponded to the 600 bp bands; and the ES clone
(ESH29) corresponded to the 276 bp band.
(B) Sanger sequence analysis of dystrophin cDNAs from differentiated skeletal muscle cells. The IF clone (IFH30) exhibited a 1 bp insertion
(A, black arrow), the ES clone (ESH29) exhibited the conjugation of exons 43 and 46 due to the skipping of exon 45, and knockin clones
(TKII15 and CKIC2) exhibited the complete restoration of exon 44 in front of exon 45 as the healthy control.
(C) Immunofluorescence staining of skeletal muscle cells differentiated from the corrected clones. A z axis section of the confocal mi-
croscopy image shows submembrane localization of the dystrophin protein in the healthy control and all corrected clones, but not in the
uncorrected original DMD iPSCs. The cells were stained by DAPI, a marker of skeletal differentiation (myosin heavy chain [MHC]), in red and
an antibody that detects the rod domain of dystrophin (DYS1) in green. Scale bar, 50 mm.
(D) Western blot analysis to estimate the molecular weight of the dystrophin protein in the corrected clones. Expected molecular weight:
420 kDa for the reading-frame-corrected clone, 414 kDa for the exon-skipping clone, and 427 kDa for the exon 44 knockin clones and
healthy control. An anti-dystrophin C terminus (amino acids 3661–3677) antibody was used to detect dystrophin protein, and an anti-
a-SMA antibody was used as the sample loading control.
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Together, our data indicate that genetically corrected iPSCs
can express the dystrophin protein once they differentiate
into myogenic cells.DISCUSSION
Here, we have demonstrated that three distinct methods
can correct the dystrophin gene: exon skipping, frameshift-150 Stem Cell Reports j Vol. 4 j 143–154 j January 13, 2015 j ª2015 The Auting, and exon knockin. All three approaches restored dys-
trophin protein expression in differentiated skeletalmuscle
cells. However, only the exon knockin approach restored
the full-length dystrophin protein. We took advantage
of the ability to expand iPSCs limitlessly and achieved a
high percentage of knockin events by incorporating a
drug selection system (up to 84% in the present study).
Based on its precision and efficacy, we conclude that the
knockin approach is preferable for correcting the dystro-
phin gene in iPSCs.hors
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CRISPR-sgRNA can bind to DNA despite a few base mis-
matches (Hsu et al., 2013). Therefore, it is critical to target
a unique region in the genome with a minimal number
of off-targets, as otherwise multiple targets may be cleaved.
Several web-based programs can be used to search for off-
target sites with a given target sequence region (e.g.,
CRISPR Design Tool [Hsu et al., 2013], Cas-OFFinder [Bae
et al., 2014b], and E-CRISP [Heigwer et al., 2014]). However,
these programs provide the predicted number of off-target
sites only within a small region (typically 500 bp) at any
given time. Our unique k-mer approach allows the visuali-
zation of targetable regions in the entire genome, so users
can select the targetable region(s) before checking the
number of off-targets with other programs.
The risk of off-target mutagenesis is one of the most
important obstacles to the therapeutic use of programma-
ble nucleases. We performed a T7EI assay and amplicon
deep sequencing to detect rare mutations at the target
site, but did not detect an increased mutation rate from
our results. To further assess the risk of target-sequence-in-
dependent off-target mutations, we employed combina-
tions of rigorous genome-wide mutation analyses, such
as the G-band for karyotyping, SNP array for detecting
CNVs, and exome sequencing for searching SNVs and small
indels. Since none of these methods alone sufficiently
covers the large spectrum of mutations (from the single-
nucleotide level to the chromosome level), it is important
to combine several methods before applying gene therapy.
To achieve a therapeutic effect with genetically corrected
iPSCs for an autologous ex vivo gene therapy approach, we
must still overcome several hurdles, such as the successful
transplantation of iPSC-derived myogenic cells. Since
MYOD1-induced muscle cells from iPSCs have the ability
to fuse (Goudenege et al., 2012; Tanaka et al., 2013), a
corrected copy of the dystrophin gene may be able to con-
tribute to an entire myofiber. Moreover, for long-term re-
population, the differentiation of iPSCs toward muscle
progenitor cells (i.e., satellite cells) could be ideal for
restoring damaged muscle in DMD patients (Darabi et al.,
2012). In addition, an immunogenic response to the newly
corrected gene product is possible (Mendell et al., 2010),
although the response may be hindered by transient
immunosuppression.
In summary, we have demonstrated the restoration of
the dystrophin protein in patient-derived iPSCs by three
different approaches. TALEN and CRISPR were equally
effective and hadminimal effects on off-targetmutagenesis
when they were targeted to a unique sequence region. Our
efficient and precise correction method using TALEN and
CRISPR technologies should provide a framework for
future ex vivo gene therapy using patient-specific human
iPSCs.Stem CeEXPERIMENTAL PROCEDURES
Generation of Integration-Free DMD iPSCs
DMDfibroblasts were derived from aDMDpatient lacking exon 44
of the dystrophin gene after the subject providedwritten informed
consent. The use of patient-derived samples and the genomic anal-
ysis were approved by the Ethics Committee of Kyoto University
(no. 824 and no. G259, respectively). DMD fibroblasts were
cultured in Dulbecco’s modified Eagle’s medium supplemented
with 5% fetal bovine serum. To generate integration-free DMD
iPSCs, we transfected 63 105 DMDfibroblasts with three episomal
vectors (pCXLE-hOCT3/4-shp53-F, pCXLE-hSK, and pCXLE-hUL)
by Neon electroporation (1650 V, 10ms, 3 pulses) as described pre-
viously (Okita et al., 2011). The iPSC colonies that emerged were
picked up and plated onto 24-well plates with feeders on day 31
and then expanded.
To screen for iPSC clones that were negative for residual episomal
vectors, iPSC pellets were lysed with 500 ml of lysis solution
(200 mg ml1 proteinase K) at 55C for 3–16 hr. Genomic DNA
was purified by phenol-chloroform extraction and ethanol precipi-
tation, and then used for quantitative PCR analyses using the
primers listed in Table S6. An episomal plasmid was used to deter-
mine the standard curve, and DMD-iPSC clones with fewer than
0.01 copies were deemed integration-free iPSC clones. The original
DMD-iPSC #1 (clone ID: CiRA00111) and the corrected clones,
including the IF clone IFD28 (clone ID: CiRA00111-IF-D28), ES clone
ESH19 (clone ID: CiRA00111-ES-H19), TALEN-mediated knockin
clone TKII15 (clone ID: CiRA00111-TKI-I15), and CRISPR-mediated
knockin clone CKIC2 (clone ID: CiRA00111-CKI-C2), will be avail-
able from the RIKEN BRC Cell Bank (cell no. HPS0383-HPS0387).
Unique k-mer Sequence Database
To identify unique sequence regions and avoid repeated sequences
in the human genome, we generated all possible combinations of
small k-mer sequences (%16 bp) by a custom Perl script. We then
mapped the k-mer sequences onto the human genome (hg19) us-
ing Bowtie (Langmead et al., 2009), with no mismatch allowed.
Only uniquely mapped k-mer sequences were pooled as the data
set. To visually show the stack of unique k-mer sequences, themap-
ping data were converted to the BEDGRAPH format by genomeCo-
verageBed and then converted to TDF format by igvtools or to the
bigWig format by bedGraphToBigWig. The unique k-mer sequence
(Unik) database will be available on our website (https://apps.cira.
kyoto-u.ac.jp/igeats).
Transfection of TALEN and CRISPR into Human iPSCs
Target iPSCs were pretreated with a ROCK inhibitor (Y-27632;
Sigma) at 10 mM for at least 1 hr before electroporation. The cells
were washed with PBS and treated with CTK solution for 1–
3 min at 37C to remove feeders and then were washed with PBS
twice. Next, the iPSCs were further dissociated into single cells
by a 0.25% Trypsin solution for 5–8 min at 37C and were neutral-
ized with culture medium containing 10% fetal bovine serum. We
electroporated 10 mg of nuclease-expressing plasmids (TALENs:
5 mg left and 5 mg right; CRISPR: 5 mg Cas9 and 5 mg sgRNA) and
5 mg donor plasmid (if applicable) into 1 3 106 cells using a
NEPA 21 electroporator (poring pulse: pulse voltage, 125 V; pulsell Reports j Vol. 4 j 143–154 j January 13, 2015 j ª2015 The Authors 151
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one well of a six-well plate with feeders in the presence of 10 mM
Y-27632 for 1–2 days.
Analysis of Indel Patterns by Deep Sequencing
The dystrophin gene target region was PCR amplified with barcod-
ing primers (DMD-MiSeq-Rd1-fwd1 and DMD-MiSeq-Rd2-rev1)
and then adaptor primers (Multiplex P5 fwd and Multiplex P7
rev) using a high-fidelity PCR enzyme. The resultant PCR products
were gel purified and quantified by a Qubit 2.0 Fluorometer (Life
Technologies) and the KAPA Library Quantification Kit for Illu-
mina (KAPA Biosystems). Each DNA sample was adjusted to
2 nM and denatured by 0.2 N NaOH solution for 5 min. The sam-
ples were further diluted to 12 pM, mixed with 4 pM of PhiX
spike-in DNA, and run on MiSeq using the MiSeq Reagent Kit
v2 for 23 150 bp sequencing. The generated FASTQ sequence files
were filtered by the fastq_quality_filter program from the FASTX-
Toolkit to remove low-quality sequencing reads. After removal of
the PhiX sequences, the remaining sequencing reads were split
based on the barcode indices by the fastx_barcode_splitter pro-
gram. The resultant reads were mapped to the target sequences
by BWA, and the mutation patterns were extracted from the
CIGAR code and MD tag.
Frameshift Screening without a Template Donor
Genomic DNAs from the transfected iPSCs were analyzed by the
T7EI assay and restriction enzyme (XcmI) sensitivity assay to
monitor the efficiency of the nuclease-mediated mutagenesis.
Then the cells were dissociated into single cells and diluted to
200–500 cells per 10 cm dish with feeders. The subclonal colonies
that emerged were picked on days 11–13 after reseeding. From
the genomic PCR sequencing, the indels at dystrophin exon 45
with the (3n + 2) bp deletion or (3n + 1) bp insertion (where
n is a nonnegative integer) were further expanded for later
experiments.
TALEN- or CRISPR-Mediated Exon 44 Knockin
For the knockin experiment, 5 mg of donor vector was cotrans-
fected with TALEN expression vectors (5 mg for left TALEN and
5 mg for right TALEN) or Cas9 and sgRNA expression vectors
(5 mg for Cas9 and 5 mg for sgRNA) using NEPA 21 as described
above. Hygromycin B (25 mg ml1; Invitrogen) selection was
applied after iPSC colonies were recovered (4–5 days after transfec-
tion). The resulting hygromycin-resistant colonies were dissoci-
ated into single cells and plated at 200–500 cells per 10 cm dish
with feeders. Each subclone was screened by genomic PCR (with
P1-P2 primer pairs, amplifying a fragment from upstream of the
30 arm to the EF1a-promoter, and P3-P4 primer pairs, amplifying
a fragment from exon 44 to downstream of the 50 arm). Homolo-
gous recombinants were further verified by Southern blot analysis
using EcoRI and probe intron 45. After establishing the single-copy
knockin clones, we electroporated the cells with 10 mg of the Cre
expression vector pCXW-Cre-puro using NEPA 21. Clone isolation
was carried out as described above, and excision of the hygromy-
cin-selection cassette was confirmed by PCR screening with
primers P1 and P4 and Southern blot analysis with EcoRI digestion
and probe intron 45.152 Stem Cell Reports j Vol. 4 j 143–154 j January 13, 2015 j ª2015 The AutSkeletal Muscle Differentiation by Dox-Inducible
MYOD1
The induction of skeletal muscle differentiation from iPSCs was
described previously (Tanaka et al., 2013). Briefly, a Dox-inducible
MYOD1-expressing piggyBac vector, PB-TetO-MyoD,was coelectro-
porated with the piggyBac transposase vector PBaseII (Matsui et al.,
2014) using NEPA 21 (125 V, 5 ms). G418 (Calbiochem) selection
(100 mg ml1) was applied to select stable PB-TetO-MyoD clones.
Among the several G418-resistant clones, we screened for clones
with a high mCherry induction rate upon addition of 1 mg ml1
doxycycline (Funakoshi). Successful differentiation was confirmed
by a spindle-shape-like morphology and immunocytochemical
staining with myosin heavy chain (MHC) and a-skeletal muscle
actin (a-SMA) antibodies on day 9 postdifferentiation.
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